Research programme: eczema vaccine - Immune Response BioPharmaAlternative Names: DermaVax; IR-444
Latest Information Update: 05 Feb 2014
At a glance
- Originator Immune Response BioPharma
- Class Vaccines
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eczema
Most Recent Events
- 13 Dec 2013 Preclinical trials in Eczema in USA (Parenteral)